1 October we become SureStone CapitalSame team, same ABN. Our website and email addresses move to surestone.com.au.
Preparing video
Key points:
FDA clearance paves the way for phase two clinical trials of Imagion’s cancer imaging agentRenewed Siemens Healthineers partnership aims to enhance MRI-based early cancer detectionRecent $3.75m raise funds initial trial stages with open-label data updates expectedProulx targets a strategic commercial partner as the main future value catalyst
Imagion Biosystems (ASX:IBX) is, in CEO Bob Proulx’s view, entering a key clinical and commercial phase following fresh clearance from the US Food and Drug Administration to begin phase two trials of its cancer imaging agent. Proulx states that renewing the company’s collaboration with Siemens Healthineers is central to advancing this next stage, as the partner provides high‑resolution MRI technology that, combined with Imagion’s agent, is intended to improve early and accurate cancer detection.
Proulx explains that current MRI scans often struggle to distinguish whether a lesion is truly cancerous. Imagion’s nanoparticle-based imaging agent is described as designed to bind only to specific cancer cells, signalling when a tumour is malignant. The phase two trial, structured in three parts and run as an open-label study, is expected by Proulx to generate interim endpoints that can be reported to the market as patient cohorts are completed, potentially supporting valuation uplift if results are favourable.
Following a recent $3.75 million capital raise from sophisticated investors and family offices, Proulx expects the company to commence enrolment, dose initial patients and deliver early data over the next six months. Proulx views the major value inflection as arriving when sufficient clinical evidence attracts a strategic pharmaceutical or imaging partner to commercialise the technology globally.
